LUNAR®-FLU (ARCT-2138)
Seasonal Influenza
Phase 1Status Unknown
Key Facts
About Arcturus Therapeutics
Arcturus Therapeutics is a fully integrated, commercial-stage biotech focused on developing mRNA medicines for infectious diseases and rare genetic disorders. Its key achievement is the global approval of KOSTAIVE®, the world's first authorized self-amplifying mRNA COVID-19 vaccine, validating its proprietary technology platforms. The company's strategy is to leverage its LUNAR® delivery and STARR™ saRNA platforms to build a diversified pipeline, advance wholly-owned rare disease programs, and expand through strategic partnerships for vaccines and therapeutics.
View full company profileTherapeutic Areas
Other Seasonal Influenza Drugs
| Drug | Company | Phase |
|---|---|---|
| mRNA-based Influenza Vaccine | Sanofi | Phase 3 |
| mRNA-1010/1011 | Moderna | Phase 3 |
| Standalone Seasonal Influenza Vaccine | Novavax | Phase 3 |
| Oral Influenza Vaccine | Vaxart | Phase 2 |